Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedFooter revision updated to v3.3.2, replacing the previous v3.3.1.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.3.1 replaces the previous v3.2.0 on the page. No substantive study details or functionality changes are indicated.SummaryDifference0.1%

- Check29 days agoChange DetectedDeleted the government funding lapse notice that was previously displayed on the page; it had directed users to cc.nih.gov and opm.gov for operating status updates.SummaryDifference0.4%

- Check43 days agoChange DetectedResults for NCT02289209 were posted on ClinicalTrials.gov on 2025-03-06, including updated outcome measures and data tables.SummaryDifference0.4%

- Check71 days agoChange DetectedMajor change: new government operating status notice and updated version to v3.2.0. Minor changes: removal of a specific resource title and old version label.SummaryDifference3%

- Check79 days agoChange DetectedReworded the core topic to 'Squamous cell carcinoma of the head and neck' and updated the revision/version to v3.1.0.SummaryDifference0.5%

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.